Beigene Ltd (NASDAQ:BGNE) Director Bros. Advisors Lp Baker acquired 1,980,198 shares of Beigene stock in a transaction that occurred on Thursday, January 18th. The stock was acquired at an average cost of $101.00 per share, for a total transaction of $199,999,998.00. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Shares of Beigene Ltd (NASDAQ BGNE) opened at $118.26 on Tuesday. The company has a current ratio of 9.33, a quick ratio of 9.27 and a debt-to-equity ratio of 0.20. The company has a market cap of $5,380.00 and a price-to-earnings ratio of -90.27. Beigene Ltd has a 1 year low of $31.90 and a 1 year high of $120.00.
Beigene (NASDAQ:BGNE) last issued its quarterly earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million for the quarter, compared to the consensus estimate of $1.55 million. During the same period last year, the company posted ($1.08) EPS. equities research analysts expect that Beigene Ltd will post -2.04 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of BGNE. ProShare Advisors LLC raised its holdings in shares of Beigene by 2.5% during the second quarter. ProShare Advisors LLC now owns 10,118 shares of the company’s stock valued at $455,000 after purchasing an additional 246 shares during the period. Bank of Montreal Can raised its holdings in shares of Beigene by 3.8% during the fourth quarter. Bank of Montreal Can now owns 16,186 shares of the company’s stock valued at $1,581,000 after purchasing an additional 600 shares during the period. Vident Investment Advisory LLC raised its holdings in shares of Beigene by 2.6% during the third quarter. Vident Investment Advisory LLC now owns 29,191 shares of the company’s stock valued at $3,020,000 after purchasing an additional 733 shares during the period. TD Asset Management Inc. raised its holdings in shares of Beigene by 3.5% during the third quarter. TD Asset Management Inc. now owns 23,568 shares of the company’s stock valued at $2,437,000 after purchasing an additional 800 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Beigene during the third quarter valued at about $160,000. 55.32% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently weighed in on BGNE shares. Zacks Investment Research raised shares of Beigene from a “hold” rating to a “buy” rating and set a $115.00 price objective on the stock in a research note on Tuesday, October 3rd. Morgan Stanley reaffirmed an “overweight” rating and set a $95.00 price target (up previously from $87.00) on shares of Beigene in a research report on Friday, October 6th. Maxim Group reaffirmed a “buy” rating and set a $120.00 price target (up previously from $77.00) on shares of Beigene in a research report on Thursday, September 28th. Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Monday, December 11th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $83.00 price target (up previously from $58.00) on shares of Beigene in a research report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. Beigene has a consensus rating of “Hold” and a consensus price target of $96.67.
COPYRIGHT VIOLATION WARNING: This report was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.truebluetribune.com/2018/01/23/beigene-ltd-bgne-director-bros-advisors-lp-baker-buys-1980198-shares-of-stock.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.